

**PRESS RELEASE**

9 February 2026

**EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain**

- Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases
- Financing was co-led by EQT Life Sciences from the LSP Dementia Fund, together with age1 and participation from Iaso Ventures, and alongside existing investors
- Investment underscores EQT Life Sciences' commitment to high-impact therapeutics and will support Aerska's ambition to address a significant unmet need in neuroscience drug development

EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA medicines for neurological diseases. This brings Aerska's total funds raised to-date to USD 60 million, building on its seed funding announcement in October 2025.

Proceeds from the Series A will support continued development of Aerska's antibody-oligo conjugate (AOC) platform as it progresses towards the clinic, targeting neurological diseases through systemically delivered RNA interference (RNAi) therapeutics. Additionally, the funding will be used to advance its brain shuttle technology to improve delivery of RNAi therapeutics across the blood-brain barrier to treat a range of neurological diseases.

Aerska's AOC platform is pioneering systemically delivered RNA medicines capable of reaching the brain to treat neurological diseases at their source. The platform uses proprietary "brain shuttle" technology to overcome the blood-brain barrier, a fundamental challenge that has historically limited RNA therapeutics in CNS diseases. This delivery approach is designed to enable intravenous or subcutaneous administration, achieving uniform and deep brain distribution with durable target gene knockdown, unlocking new therapeutic possibilities for neurological diseases.

Jack O'Meara, CEO & Co-Founder, Aerska, said: "The ability to systemically administer RNAi therapies to the brain unlocks a powerful new approach to treating neurodegeneration. Partnering with EQT Life Sciences further strengthens our path to the clinic as we work to translate this capability into meaningful therapies for the treatment of genetically driven forms of Alzheimer's disease and other devastating brain disorders."

Philip Scheltens, MD, PhD, Partner and Head of EQT's LSP Dementia Fund, said: "For families facing diseases like Alzheimer's, Aerska's approach offers hope for preserving cognitive function and quality of life. The team's strategy of upstream intervention, combined with a focus on the genetic forms of neurological disease, positions them to transform outcomes for populations who have been underserved by current therapeutic approaches. We really look forward to working alongside Aerska to help advance this groundbreaking platform."

As part of the financing, Arno de Wilde, MD, PhD, MBA, Managing Director at EQT Life Sciences, Philip Scheltens, MD, PhD, Partner and Head of EQT's LSP Dementia Fund at EQT Life Sciences, and Alex Colville, PhD, General Partner at age1, will join Aerska's Board of Directors.

**Contact**

EQT Press Office, [press@eqtpartners.com](mailto:press@eqtpartners.com)

**About EQT Life Sciences**

*EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients. The LSP Dementia Fund (USD 297 million) started in 2020 and has a dedicated team of neurologists and neuroscientists focused on investing in therapeutics targeting neurodegenerative diseases.*

*For more information, go to <https://eqtgroup.com/private-capital/life-sciences/>*

**About Aerska**

*Aerska is a biotechnology company pioneering RNA medicines to treat, delay and prevent diseases of the brain. The company is leveraging advances in 'brain shuttles' to enable targeted delivery of next-generation RNAi therapeutics to the CNS. By silencing the genes that cause harm, Aerska aims to preserve the minds, protect the memories, and enable our loved ones to live longer, healthier lives. Aerska is headquartered in Dublin, Ireland, with research operations in London, UK. For more info, visit [www.aerska.com](http://www.aerska.com).*